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Background: Both medication and surgery are effective treatments for severe gastro-oesophageal reflux
disease (GORD). Postoperative risks have contributed to decreased use of antireflux surgery. The aim of
this study was to assess short-term mortality following primary laparoscopic fundoplication.
Methods: This was a population-based nationwide cohort study including all Swedish hospitals that
performed laparoscopic fundoplication between 1997 and 2013. All patients aged 18–65 years withGORD
who underwent primary laparoscopic fundoplication during the study interval were included. The primary
outcome was absolute all-cause and surgery-related 90- and 30-day mortality. Secondary outcomes were
reoperation and length of hospital stay. Logistic regression was used to calculate odds ratios with 95 per
cent confidence intervals of reoperation within 90days and prolonged hospital stay (4 days or more).
Results: Of 8947 included patients, 5306 (59⋅3 per cent) were men and 551 (6⋅2 per cent) had significant
co-morbidity (Charlson score above 0). Median age at surgery was 48 years, and median hospital stay was
2 days. The annual rate of laparoscopic fundoplication decreased from 15⋅3 to 2⋅4 patients per 100 000
population during the study period, whereas the proportion of patients with co-morbidity increasedmore
than twofold. All-cause 90- and 30-day mortality rates were 0⋅08 per cent (7 patients) and 0⋅03 per cent
(3 patients) respectively. Only one death (0⋅01 per cent) was directly surgery-related. The 90-day
reoperation rate was 0⋅4 per cent (39 patients). Co-morbidity and older age were associated with an
increased risk of prolonged hospital stay, but not reoperation.
Conclusion: This population-based study revealed very low mortality and reoperation rates following
primary laparoscopic fundoplication in the working-age population. The findings may influence clinical
decision-making in the treatment of severe GORD.
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Introduction
Gastro-oesophageal reflux disease (GORD) is a public
health concern, affecting 10–20 per cent of all adults in
Western populations, and the rate is increasing1. GORD
is associated with limitations to quality of life, and high
costs for patients, healthcare and society. There is also a
risk of severe complications following GORD, including a
risk of oesophageal adenocarcinoma, which is an increas-
ingly common cancer, with a poor prognosis1–4. A recent
meta-analysis5 found that weekly and daily reflux symp-
toms entailed a fivefold and sevenfold increased risk of
developing oesophageal adenocarcinoma respectively.
The two most effective treatment options for severe
GORD are continuous and long-term medication with
proton pump inhibitors (PPIs), and antireflux surgery with
laparoscopic fundoplication2,3. In current practice, surgery
is typically recommended only to patients with GORD
who experience an inadequate response to PPIs or who
object to long-term use of PPIs. The literature indicates
that laparoscopic fundoplication may be superior to PPI
treatment in terms of reflux symptoms, oesophageal acid
exposure, overall andGORD-associated quality of life, pre-
vention of oesophageal adenocarcinoma, and long-term
cost-effectiveness3,6. The risk of mortality and morbidity
following antireflux surgery has contributed strongly to its
considerably decreased use in the past decade2,7,8, although
studies2,7–9 suggest that surgical therapy may be underuti-
lized. The reported overall perioperative and 30-day mor-
tality rate is 0⋅45 per cent2,7,8,10, and severe complications
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occur in up to 4 per cent2,3,11, which is not negligible for a
benign disorder.
However, studies addressing mortality and morbid-
ity following antireflux surgery are old, or limited
single- or multiple-institution series at best. Only two
population-based studies are available; one7 assessed
inpatient postoperative mortality and morbidity, and
the other10 assessed 30-day mortality. Yet, with current
improvements in postoperative care, 90-day mortality
might be a better assessment of postoperative mortality in
upper gastrointestinal surgery12.
The aim of the present study was to assess 90-day
mortality and morbidity after primary laparoscopic fundo-
plication for GORD in a recent and unselected nationwide
cohort with complete follow-up of all participants.
Methods
This was a nationwide, Swedish population-based, cohort
study investigating the absolute risk of mortality and
reoperation for up to 90 days after primary laparoscopic
fundoplication during the study period, from 1 January
1997 to 31 December 2013. In addition, the relative risks
of reoperation and prolonged postoperative hospital stay
were determined.
The study cohort consisted of all patients aged
18–65 years who underwent laparoscopic fundoplica-
tion for a recorded diagnosis of GORD in Sweden during
the study interval. Data were collected from nationwide
Swedish registries. The unique ten-digit personal iden-
tity number assigned to each resident in Sweden upon
birth or immigration enabled linkages of individuals’ data
between registries. The indication for surgery, the surgical
technique used, and the cause of death were validated by
retrieval of medical records for patients who died within
90 days after surgery during the study period.
The study was approved by the Regional Ethical
Review Board in Stockholm, Sweden (reference number
2014/234-31).
Data retrieval and definition of exposure
All eligible patients (those who underwent laparoscopic
fundoplication for GORD during the study period) were
identified from the Swedish Patient Registry. GORD
was used as a criterion for inclusion to avoid including
fundoplication for other indications. The vast major-
ity of the excluded patients had a fundoplication in
association with oesophagogastric myotomy, mainly for
achalasia. The Patient Registry records in-hospital and out-
patient care since 1964, and includes discharge diagnoses,
Table 1 Characteristics of patients included in the study
All
patients
90-day
mortality
90-day
reoperation
Total 8947 (100) 7 (0⋅08) 39 (0⋅4)
Age at surgery (years)* 48 (38–55) 42 (41–61) 51 (39–56)
Sex ratio (M : F) 5306 : 3641 4 : 3 21 : 18
Co-morbidity (Charlson score)
0 8396 (93⋅8) 4 (57) 35 (90)
1 488 (5⋅5) 2 (29) 4 (10)
≥2 63 (0⋅7) 1 (14) 0 (0)
Time interval for surgery
1997–2002 5287 (59⋅1) 2 (29) 22 (56)
2003–2008 2853 (31⋅9) 2 (29) 14 (36)
2009–2013 807 (9⋅0) 3 (43) 3 (8)
Length of hospital stay (days)* 2 (1–3) 11 (3–19) 6 (3–10)
Values in parentheses are percentages unless indicated otherwise. *values
are median (i.q.r.).
co-morbidities, surgical procedures, hospitalization dates
and demographic data.
The coverage of in-hospital care has been complete
nationwide since 1987, and the coverage of outpatient
specialist care reached 100 per cent in 200113. The doc-
umented data regarding both diagnoses and surgical
procedures have excellent completeness and validity13,14.
The Nordic Medico-Statistical Committee (NOMESCO)
Classification of Surgical Procedures, which provides
separate codes for laparoscopic and open antireflux pro-
cedures, was introduced to the Patient Registry in 1997,
thus determining the start date of the study. Laparoscopic
fundoplication was identified using the NOMESCO
code JBC-01, and reoperations were identified with any
NOMESCO code beginning with JW. The Patient Reg-
istry does not contain data on the subtype of fundoplication
performed, for instance procedures according to Nissen,
Toupet or other.
Data needed to calculate the rates of laparoscopic fundo-
plication per 100 000 inhabitants aged 18–65 years in
Sweden were derived from the Patient Registry and the
Swedish Registry of the Total Population. The latter reg-
istry has had 100 per cent nationwide completeness since
194715. Diagnoses of GORD were retrieved from the
Patient Registry (using ICDversions 7–10):GORD, heart-
burn, hiatal hernia, oesophagitis and Barrett’s oesophagus.
Outcomes
Date and causes of death were identified from the Swedish
Causes of Death Registry. This registry contains informa-
tion on all deceased Swedish residents since 1952, with a
completeness of 99⋅2 per cent16. All data in this registry
are coded according to the ICD system.
Data on the secondary outcomes (postoperative
reoperation and prolonged hospital stay) were retrieved
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Fig. 1 Laparoscopic fundoplications performed in men and women with gastro-oesophageal reflux disease in Sweden from 1997 to
2013; table below shows 90-day reoperations and 90-day mortality
from the Patient Registry. Postoperative reoperation was
defined as any surgery conducted within 90 days after the
primary fundoplication. Patients who died within 90 days
of surgery were excluded from the analyses address-
ing reoperation. Prolonged hospital stay was defined
as duration of stay of 4 days or more after laparoscopic
fundoplication, as this exceeds the routine length of
stay2,17. Length of hospital stay was calculated from the
admission and discharge dates in the Patient Registry. To
include any in-hospital days following discharge spent at
another ward or hospital, any subsequent in-hospital care
following admission for up to 1 day after discharge from
the surgical ward was also included.
Co-variables
The study co-variables were sex, age, co-morbidity, date
of admission and length of hospital stay, all collected from
the Patient Registry. Co-variables were chosen based on
known cause–effect relationships for increased morbidity
and mortality in the previous literature. The co-variables
and the model were determined in the study protocol
before data collection to ensure nominal coverage of the
confidence intervals (c.i.).
Co-morbidity was defined using the Charlson
co-morbidity score, a well validated composite variable for
quantification of co-morbidity, which is based on specific
diagnosis codes18–21. Patients were categorized into three
Charlson co-morbidity score groups (0, 1, or 2 or above),
a categorization that distinguishes the groups in terms of
risk of mortality18.
Statistical analysis
The analyses were conducted using the statistical software
SAS® version 9.3 (SAS Institute, Cary, North Carolina,
USA) and R22. The absolute risk of death and reopera-
tion following laparoscopic fundoplication were calculated.
The low number of deaths prohibited further analyses of
short-term mortality.
A multivariable logistic regression model was used to
assess the odds ratio (OR) and 95 per cent c.i. of reop-
eration within 90 days of surgery, as well as the OR of
prolonged length of hospital stay. Adjustments were made
for the co-variables age (continuous variable), sex (male
or female), year of surgery (continuous variable) and
Charlson co-morbidity score (0, 1, or 2 or above). Model
assumptions and goodness of fit were checked formally
and graphically23. The residuals were plotted against fitted
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Fig. 3 Distribution of co-morbidity (Charlson co-morbidity
score) in patients with gastro-oesophageal reflux disease who
underwent laparoscopic fundoplication in Sweden from 1997
to 2013
values to assess (lack of) fit graphically. A check was made
for overly influential observations using a plot of Cook’s
distance versus leverage. Overdispersion was checked by
fitting a quasi-binomial instead of a binomial.
In the analysis of hospital stay, a thin-plate regression
spline was used to model the effect of year of surgery. The
number of knots was checked using a simulation approach.
Although the exact basis dimension of a thin-plate spline
is not generally critical, a sufficiently small value ensures
computational efficiency24. The simulation approach
described and implemented in the mgcv package for R
was used, as described previously25. Briefly, an estimate of
the residual variance of near neighbours was calculated.
Residuals were reshuffled a number of times to obtain the
null distribution of the differencing variance estimator
(that is, no pattern was present in the residuals given the
chosen basis dimension). All tests were two-tailed and
statistical significance was set at P< 0⋅050.
Results
In total, 8947 patients constituted the laparoscopic fundo-
plication study cohort; their median age at operation was
48 years, the majority were men (5306, 59⋅3 per cent) and
median length of hospital stay was 2 days (Table 1). Some
488 patients (5⋅5 per cent) had a Charlson score of 1,
and 63 (0⋅7 per cent) had a score of 2 or more. A total of
290 patients were excluded as a GORD-related diagnosis
was not recorded, including eight with a Charlson score
greater than 1. None of these patients died within 90 days
of surgery.
The annual number of laparoscopic fundoplication pro-
cedures decreased from 832 in 1997 to 144 in 2013 (Fig. 1),
and the number of procedures performed annually per
100 000 population decreased from 15⋅3 in 1997 to 2⋅4 in
2013 (Fig. 2). The proportion of women increased from
40⋅5 per cent in 1997 to 48⋅6 per cent in 2013. During the
study interval, the proportion of patients with a Charlson
co-morbidity score of 1 and of 2 or more increased more
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than twofold and threefold respectively (Fig. 3). The distri-
bution of age and length of hospital stay remained constant
throughout the study period.
Mortality
Seven patients died within 90 days of surgery, of whom
three died within 30 days, giving 90- and 30-day all-cause
mortality rates of 0⋅08 and 0⋅03 per cent respectively
(Table 1). One patient (0⋅01 per cent) died from a direct
surgery-related complication, acute respiratory distress
syndrome, 19 days after operation; this was the only
in-hospital death. Causes of the other six deaths were heart
failure (2 patients), suicide (2), diabetic ketoacidosis (1)
and accidental poisoning (1).
The indications for surgery and surgical technique used
in all patients who died within 90 days were validated
through medical records, and found to be accurate in
all cases. The number of all-cause deaths was no greater
than one in any of the 17 years studied (Fig. 1). None of
the deceased patients underwent reoperation. Compared
with the other patients, those who died within 90 days of
fundoplication had a longer median hospital stay (11 versus
2 days) and more co-morbidities with a Charlson score of
1 (29 versus 5⋅5 per cent respectively) and 2 or more (14
versus 0⋅7 per cent), whereas the distribution of sex and age
was similar (Table 1).
Reoperation
The reoperation rate was 0⋅4 per cent (39 of 8947) within
90 days of laparoscopic fundoplication, and also 0⋅4 per
cent (38 patients) within 30 days of surgery. In 1997,
three reoperations were conducted, reaching an annual
maximum of six in 2000, and with no more than one
per year from 2008 onwards (Fig. 1). The distribution of
age, sex and co-morbidity was similar for patients in the
90-day reoperation group and the other study participants,
whereas median length of hospital stay was greater in the
reoperation group (6 versus 2 days) (Table 1). There were
no statistically significant associations between risk of
reoperation and age, sex, year of surgery or co-morbidity
(Table 2).
Prolonged hospital stay
Co-morbidity, female sex and higher age were associated
with an increased risk of prolonged hospital stay (Table 2).
The risk of prolonged hospital stay was characterized by
a complex pattern over time, descending from increased
to decreased risk in the early to intermediate years of the
Table 2 Risk of reoperation and prolonged hospital stay following
laparoscopic fundoplication for gastro-oesophageal reflux disease
Odds ratio*
90-day
reoperation
Prolonged
hospital stay
Age at surgery 1⋅01 (0⋅98, 1⋅04) 1⋅01 (1⋅00, 1⋅01)
Year of surgery 1⋅01 (0⋅94, 1⋅09) †
Sex
F 1⋅00 (reference) 1⋅00 (reference)
M 0⋅84 (0⋅44, 1⋅61) 0⋅76 (0⋅68, 0⋅86)
Co-morbidity (Charlson score)
0 1⋅00 (reference) 1⋅00 (reference)
1 1⋅86 (0⋅65, 5⋅33) 1⋅36 (1⋅04, 1⋅66)
≥2 n.a. 2⋅27 (1⋅30, 4⋅00)
Values in parentheses are 95 per cent confidence intervals. *Adjusted for
sex, co-morbidity score, year of surgery and age at surgery. †Adjusted by
spline (approximate significance of the smooth terms: P< 2× 10−16). n.a.,
Not applicable.
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Fig. 4 Odds ratios (ORs) with 95 per cent confidence intervals for
prolonged hospital stay after laparoscopic fundoplication in
patients with gastro-oesophageal reflux disease, adjusted for sex,
co-morbidity and age at operation, 1997–2013
study, followed by a slight surge during the most recent
6 years (Fig. 4). Overall, the risk declined over the study
period, especially from the start of the study to 2005; after
2005 there was a slight increase.
Discussion
This nationwide study found very low all-cause and
procedure-related mortality rates and reoperation rate
following laparoscopic fundoplication for GORD in an
unselected patient cohort. The increasing proportion of
surgical patients with co-morbidity over time did not
translate into an increase in mortality, reoperation or
hospital stay.
Methodological strengths of the study are the nation-
wide coverage and population-based design – including
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virtually all patients with GORD who underwent laparo-
scopic fundoplication in Sweden in 1997–2013 – which
minimizes selection bias, facilitates generalizability, and
provides a large sample size. Moreover, the complete and
well maintained nationwide registries available in Sweden
enabled complete follow-up of all patients, thus avoiding
loss to follow-up.
Among potential weaknesses of the study is a risk of
clinical selection of relatively healthy patients for surgery,
yet often with particularly severe GORD. However, the
surgical cohort reflects routine clinical practice and should
have only a limited effect on the generalizability of the
results. Moreover, the increasing presence of co-morbidity
over time did not increase the risk of unfavourable
short-term outcomes. As laparoscopic fundoplication
can be performed for indications other than GORD, a
diagnosis of GORD was required for inclusion. Although
this improves the validity of the study, it also introduces
a risk of missing eligible individuals who had GORD,
but did not have this diagnosis recorded. However, this
error should be limited because discharge diagnoses need
to be recorded in the hospital discharge notes, which are
transferred to the Swedish Patient Registry. Although
adjustments for several potential confounding factors
were made, information on some other potential con-
founders was not available, including tobacco smoking,
which can increase the risk of postoperative complications.
However, long-term smoking was indirectly adjusted for
through adjustment for the Charlson co-morbidity score,
which included chronic obstructive pulmonary disorder,
a proxy diagnosis for tobacco smoking. Moreover, it is
unlikely that information on tobacco smoking would
change any of the main results. Finally, owing to the
partial lack of data regarding exact date of surgery, the
date of admission was used as a proxy. This assumption
could have resulted in slightly imprecise postoperative
follow-up dates.
A Cochrane systematic review8 including four random-
ized clinical trials, all conducted in 1997–2004 (including a
total of 519 patients with GORD), comparing laparoscopic
fundoplication and PPI treatment reported no inpatient
deaths (all trials), a 90-day reoperation rate of 3⋅7 per
cent (4 patients; 1 trial) and no reoperations within 1 year
(2 trials). Furthermore, an inpatient mortality rate of
0⋅13 per cent was calculated by the present authors based
on data from a large cohort study in the USA7, and a
population-based cohort study from Denmark10 found a
30-day mortality rate of 0⋅45 per cent, both substantially
higher than the 0⋅01 per cent found in the present study. It
was not possible to calculate mortality within 30 or 90 days
of surgery in the cohort study from the USA7, but the
inpatient complication rate for each year studied showed
a higher peak (8⋅1 versus 0⋅7 per cent in the present study)
and trough (6⋅3 versus 0 per cent respectively). The higher
inpatient mortality rate in the US study may be explained
by the inclusion of patients of older age and with greater
co-morbidity. Another cohort study from the USA2, which
evaluated mortality in patients aged less than 70 years,
showed a 30-day mortality rate of 0⋅05 per cent, which is
more comparable to that in the present study (0⋅03 per
cent). However, that study reported a higher complication
rate (1⋅8 per cent)2. Finally, an older Finnish nationwide
cohort study11 revealed a 30-day mortality rate of 0⋅04
per cent, similar to that in the present study. However,
the Finnish study did not assess surgery-related or 90-day
mortality.
The increased risk of prolonged hospital stay with higher
age and co-morbidity in this study could be explained
by the greater disposition to postoperative complications
and slower recovery in older patients compared with
younger and fitter patients. Speculatively, a higher propor-
tion of women with obesity and increased length of surgery
could explain the higher risk of prolonged hospital stay
found in female patients, as these factors correlate with
extended hospital stay in other types of upper gastrointesti-
nal surgery26.
A decreased use of fundoplication with calendar time has
also been reported in the USA, where the use of antireflux
surgery declined from 15⋅7 to 5⋅3 operations per 100 000
inhabitants between 1999 and 20107,27. This decline could
be attributed to the increased use of PPIs since the early
2000s, an easily accessible drug proven to be effective
in reflux control and with a well documented and safe
profile3,28. In addition, the potential risks of mortality and
morbidity associated with antireflux surgery appear to have
led general practitioners, gastroenterologists and possibly
also surgeons predominantly to favour PPIs over surgery
for treatment of GORD. Yet, both treatment options can
effectively counteract GORD and improve quality of life,
although surgery appears to be slightly superior in these
respects3. Recurrence of GORD is similarly common
following both treatments3, although surgery might be
more effective in preventing oesophageal adenocarcinoma
than PPI use6. Surgery might seem to be more costly
in the short term, but is perhaps more cost-effective
in the longer term3. In addition, concerns have arisen
regarding an increased risk of osteoporosis, bone fractures
and Clostridium difficile-associated diarrhoea following
long-term treatment with PPIs3.
This study has demonstrated that laparoscopic fun-
doplication offers a safe alternative to PPI therapy
for severe GORD, with a risk profile similar to that
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of other common laparoscopic procedures for benign
diagnoses in a short-term setting (appendicectomy and
cholecystectomy)2. The low risk might, at least partly, be
due to the increased specialization of surgeons involved
in minimally invasive upper gastrointestinal surgery. The
slight superiority of laparoscopic fundoplication, along
with its safety profile, and the increasingly recognized com-
plications of long-term PPI use, argue for the adoption
of a decreased threshold for recommending laparoscopic
fundoplication in patients with severe GORD, particularly
in fit patients aged less than 65 years.
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Editor’s comments
Making an informed choice when comparable treatment options exist is prudent – from both the caretaker’s per-
spective and the patient’s view. This is particularly important in the working-age population, as different risks and
perspectives come into play compared with those in older patients. When including the population aged over 70 years,
mortality rates increase for any surgical procedure. In gastro-oesophageal reflux disease (GORD), the choice of
taking a pill over having surgery has largely been in favour of the proton pump inhibitors (PPIs), as seen by the
year-on-year reduction in laparoscopic fundoplications performed worldwide. Some arguments against surgery have
been the increased mortality risk of surgery versus the apparently trivial side-effects of PPIs.
The present study highlights a very low mortality rate for laparoscopic antireflux surgery. Arguably, modern surgery
should be able to produce such excellent results in otherwise young and healthy people. In addition, the results likely
reflect careful patient selection as much as improvement in surgical management. Consequently, mortality risk should
possibly not be used to deny patients in the working-age population the opportunity of having antireflux surgery, rather
than medical treatment alone. As the real benefit of treatment for GORD (be it surgical or medical) is the ability to
resolve symptoms and restore quality of life over time, the true value of the pill versus the procedure is established
when symptom relief and maintenance of long-term effects can be compared head-to-head.
K. Søreide
Editor, BJS
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